Telix Pharmaceuticals Limited (TLX,TLX.AX) announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET). This investigational PET imaging agent is intended to help differentiate recurrent or progressive glioma (a type of brain cancer) from treatment-related changes in both adult and pediatric patients.
The resubmission includes additional data and statistical analyses requested by the FDA. Following a Type A meeting and ongoing consultation, Telix believes the new information, combined with the original dataset, adequately addresses the FDA's Complete Response Letter.
TLX101-Px has been granted Orphan Drug and Fast Track designations, underscoring its potential to address a significant unmet medical need. Although 18F-FET PET imaging is already recognized in international clinical practice guidelines for glioma imaging, there is currently no FDA-approved targeted amino acid PET agent available in the U.S. for adult or pediatric brain cancer imaging.
TLX.AX is currently trading at A$11.01, down A$0.28 or 2.48%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.